Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation

Objective: To investigate matrix metalloproteinase (MMP) proteolytic and vascular endothelial growth factor (VEGF) and receptor (VEGFR-1, VEGFR-2) angiogenetic capacity in serous borderline ovarian tumors (S-BOTs) for women with and without noninvasive implants.

Methods: The population was made up of 99 patients with S-BOTs as the primary diagnosis between 1985 and 1995, 44 of whom had noninvasive implants and 55 without implants. MMP-2, MMP-14, the type-2 tissue inhibitor of MMPs (TIMP-2), and VEGF and receptors (VEGFR-1, VEGFR-2) were examined by immunhistochemistry.

Results: Strong positive (+++) MMP-2 staining was found more frequently in women with primary S-BOTs and noninvasive implants (76%) than in those without implants (53%; p < 0.05). In contrast, staining for MMP-14 and TIMP-2 was not significantly different in the two groups. Furthermore, expression of MMP-2, MMP-14, and TIMP-2 was similar in primary tumors and in their noninvasive implants. Most tumors in both groups had no VEGF expression (84% in the noninvasive implant group and 82% in the group without implants), while moderate (++) to strong (+++) expression of VEGFR-1 and VEGFR-2 was detected in 79% and 94% of the two tumor groups, with no significant difference between the groups.

Conclusions: Enhanced MMP-2 was seen in primary S-BOT with noninvasive implants. The presence of noninvasive implants was prognostic for disease-free survival.

MMP-2, MMP-14, TIMP-2, VEFG, VEGFR-1, VEGFR-2; Ovarian neoplasm; Borderline tumor; Population-based; Epithelial; Noninvasive implants

[1] Sherman M.E., Berman J., Birrer M.J. et al.: "Current challenges and opportunities for research on borderline ovarian tumors" Hum. Pathol., 2004, 35, 961.

[2] Cancer in Norway 2004. Cancer Registry of Norway 2006.

[3] Paulsen T., Kaern J., Kjaerheim K. et al.: "Symptoms and referral of women with epithelial ovarian tumors". Int. J. Gynaecol. Ohstet., 2005, 88, 31.

[4] Eichhorn J.H., Bell D.A., Young R.H. et al.: "Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns". Am. J. Surg. Pathol., 1999, 23, 397.

[5] Prat J.: "Serous tumors of the ovary (borderline tumors and carcinomas) with and without micropapillary features". Int. J. Gynecol Pathol., 2003, 22, 25.

[6] Stetler-Stevenson W.G., Aznavoorian S., Liotta L.A.: "Tumor cell interactions with the extracellular matrix during invasion and metastasis". Annu. Rev. Cell. Biol., 1993, 9541.

[7] Turpeenniemi-Hujanen T.: "Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers". Biochimie， 2005, 87 (3-4), 287.

[8] Reuben P.M., Cheung H.S.: "Regulation of matrix metalloproteinase (MMP) gene expression by protein kinases". Front Biosci., 2006, 111199.

[9] Barnhill R.L., Piepkorn M.W., Cochran A.J. et al.: "Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases". Arch. Dermatol., 1998, 134, 991.

[10] Udagawa T., Fernandez A., Achilles E.G. et al.: "Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy". FASEB J., 2002, 16, 1361.

[11] Van den Steen P.E., Dubois B., Nelissen I. et al.: "Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9)". Crit. Rev. Biochem. Mol. Biol., 2002, 37, 375.

[12] Allan J.A., Docherty A.J., Barker P.J. et al.: "Binding of gelallnases A and B to type-I collagen and other matrix components" Biochem. J., 1995, 309 (Pt 1), 299.

[13] Murphy G., Crabbe T.: "Gelatinases A and B". Meth. Enzymol., 1995, 248470.

[14] Strongin A.Y., Collier I., Bannikov G. et al.: "Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease". J. Biol. Chem., 1995, 270, 5331.

[15] Bjorklund M., Koivunen E.: "Gelatinase-mediated migration and invasion of cancer cells". Biochim. Biophys Acta, 2005, 1755, 37.

[16] Woessner J.F. Jr.: "Matrix metalloproteinases and their inhibitors in connective tissue remodeling". FASEB J., 1991, 5, 2145

[17] Lehti K., Lohi J., Valtanen H. et al.: "Proteolytic processing of membrane-type-I matrix metalloproteinase is associated with gelatinase A activation at the cell surface". Biochem. J., 1998, 334 (Pt 2), 345.

[18] Nakayama K., Takebayashi Y., Nam如T. et al.: "Comprehensive allelotype study of ovarian tumors of low malignant potential: potential differences in pathways between tumors with and without genetic predisposition to invasive carcinoma". Int. J. Cancer, 2001, 94 (4), 605.

[19] Gadducci A., Viacava P., Cosio S. et al.: "Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma". Anticancer Res., 2003, 23 (3C), 3001.

[20] Ramakrishnan S., Subramanian I.V., Yokoyama Y. et al.: "Angiogenesis in normal and neoplastic ovaries". Angiogenesis, 2005, 1.

[21] Bamberger E.S., Perrett C.W.: "Angiogenesis in epithelian ovarian cancer". Mot. Pathol., 2002, 55, 348.

[22] Wu M., Xu G., Xi L. et al.: "Down-regulation of MTl-MMP expression suppresses tumor cell invasion in metastatic human SW626 ovarian cancer cells". Oneal. Rep., 2006, 15, 501.

[23] Tumors of the Ovaries and Peritoneum. In: Tavassoli F.A., Devilee P. (eds.). Pathology & Genetics Tumours of the Breast and Female Genital Organs. I" edition, Lyon: I ARC Press, 2003, 113.

[24] Seidman J.D., Soslow R.A., Vang R. et al.: "Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images". Hum Pathol., 2004, 35 (8), 918.

[25] Ortiz B.H., Ailawadi M., Colitti C. et al.: "Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors". Cancer Res., 2001, 61, 7264.

[26] Gu J., Roth L.M., Younger C. et al.: "Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential". J. Natl Cancer Inst., 2001, 93, 1147.

[27] Shih I.,Kurman R.J.: "Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis". Am. J. Pathol., 2004, 164, 1511.

[28] Shih I., Kurman R.J.: "Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges". Clin. Cancer Res., 2005, 11, 7273.

[29] Gotlieb W.H., Chetrit A., Menczer J. et al.: "Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer". Gynecol. Oncol., 2005, 97, 780.

[30] Makar A.P.,B aekelandt M.,T rope C.G. et al.: "The prognostic significance of residual disease,F IGO substage,t umor histology,and grade in patients with FIGO Stage III ovarian cancer". Gynecol. Oncol., 1995, 56, 175.

[31] Bell K.A., Smith S.A., Kurman R.J.: "Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas". Am. J. Surg. Pathol., 2001, 25, 419.

[32] Altman D.G.: "Practical Statistics for Medical Research". 1" edition, London: Chapman & Hall, 1991.

[33] Sounni N.E., Devy L., Hajitou A. et al.: "MTl-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression". FASEB J., 2002, 16, 555.

[34] Belotti D., Paganoni P., Manenti L. et al.: "Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation". Cancer Res., 2003, 63, 5224.

[35] Ogawa S., Kaku T., Kobayashi H. et al.: "Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma". Cancer Lett., 2002, 176, 111.

[36] Maatta M., Santala M., Soini Y. et al.: "Matrix metalloprotemases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors". Tumour Biol., 2004, 25, 188.

[37] Garzetti G.G., Ciavattini A., Lucarini G. et al.: "Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors". Cancer, 1999,8 5, 2219.

[38] Davidson B., Goldberg I., Gotlieb W.H. et al.: "High levels of MMP-2, MMP-9, MTI-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma". Clin. Exp. Metastasis, 1999, 17, 799.

[39] Davidson B., Goldberg I., Gotlieb W.H. et al.: "The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma". Mol. Cell. Endocrinol., 2002, 187, 39.

[40] Lengyel E., Schmalfeldt B., Konik E. et al.: "Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer". Gynecol. Oncol., 2001, 82, 291.

[41] Wu X., Li H., Kang L. et al.: Acti .: "Activated matrix metalloproteinase- 2-a potential marker of prognosis for epithelial ovarian cancer". Gynecol. Oneal., 2002, 84, 126.

[42] Monig S.P., Baldus S.E., Hennecken J.K. et al.: "Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma". Histopathology, 2001, 39, 597.

[43] Mendes 0., Kim H.T., Stoica G.: "Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model". Clin. Exp. Metastasis, 2005, 22, 237.

[44] Davidson B., Konstantinovsky S., Nielsen S. et al.: "Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression". Clin. Cancer Res., 2004, 10, 7335.

[45] Sier C.F., Kubben F.J., Ganesh S. et al.: "Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma". Br. J. Cancer, 1996, 74,413.

[46] Wollina U., Hipler U.C., Knoll B. et al.: "Serum matrix metalloproteinase-2 in patients with malignant melanoma". J. Cancer Res. Clin. Oncol., 2001, 127, 631.

[47] Singer G., Oldt R. III, Cohen Y. et al.: "Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma". J. Natl. Cancer Inst., 2003, 95, 484.

[48] Gilks C.B.: "Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases". Int. J. Gynecol. Pathol., 2003, 22, 29.

[49] Zanetta G., Rota S., Chiari S. et al.: "Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study". J. Clin. Oncol., 2001, 19, 2658.

[50] Matrisian L.M., Sledge G.W. Jr., Mohla S.: "Extracellular proteolysis and cancer: meeting summary and future directions". Cancer Res., 2003, 63, 6105.